论文部分内容阅读
在动物实验基础上，以１３１Ⅰ标记抗人肝癌单克隆抗体ＨｅｐａｍａⅠ进行人体显像研究．单抗系小鼠ＩｇＧ１，裸鼠实验显示有良好的肿瘤定位效果。１８例原发性肝癌（ＰＨＣ）患者，以Ｓｅｌｄｉｎｓｅｒｓ法经肝固有动脉注入１３１Ⅰ－ＨｅｐａｍａⅠ，平均剂量为３５５ＭＢｑ／１．５ｍｇＩｇＧ１，术后行全身及肝区γ显像．测定全身重要脏器和癌区的放射性计数比值．结果：显像阳性率７７．７％，最佳时间为注入后９６小时，癌／肝比值在第４８小时为１．６５±０．３３，第９６小时为４．３８±１．４８，第２４０小时为２．２２±０．５７．本研究提示ＨｅｐａｍａⅠ在人体内与肝癌组织有较好亲和力．
On the basis of animal experiments, 131I-labeled anti-human hepatocellular carcinoma monoclonal antibody Hepama I was used for human imaging studies. Mab monoclonal mouse IgG1, nude mice experiments have shown good tumor localization effect. Eighteen patients with primary liver cancer (PHC) were treated with 131I-HepamaI via the hepatic artery by Seldinsers method. The average dose was 355MBq / 1.5mg IgG1. Whole body and liver γ imaging were performed after operation. Determination of the body’s vital organs and cancer area radioactive count ratio. Results: The imaging positive rate was 77.7%, the best time was 96 hours after injection, the ratio of cancer / liver was 1.65 ± 0.33 at 48 hours, 4.38 ± 1.48 at 96 hours, 240 hours was 2.22 ± 0.57. This study suggests that Hepama I has good affinity with HCC in the human body.